Carbidopa/levodopa dose elevation and safety concerns in Parkinson’s patients: a cross-sectional and cohort design

David W Brodell,1 Nicole T Stanford,1 Charles E Jacobson,1 Peter Schmidt,2 Michael S Okun1

ABSTRACT
Objective: Sinemet, a combination drug containing carbidopa and levodopa is considered the gold standard therapy for the treatment of Parkinson’s disease (PD). When approved by the Food and Drug Administration (FDA) in 1988, a maximum daily dosage limit of 800 mg (eight tablets) of the 25/100 carbidopa/levodopa formulation was introduced. Overall, the FDA approval was a historic success; however, the pill limit has been hardcoded into many online medical record systems. This study investigates the 800 mg threshold by using a prospectively collected database of patient information.

Design: A retrospective cohort study: (Part I) cross-sectional, (Part II) longitudinal.

Setting and participants: PD patients at a Movement Disorders Center in a large academic, tertiary medical setting.

Outcome measures: An analysis was performed using carbidopa/levodopa at dosages below and above the 800 mg threshold. A secondary analysis was then performed using two consecutive clinic visits to determine the effects of crossing the 800 mg threshold. Comparisons were made on standardised scales.

Results: There was no significant difference in motor, mood and quality-of-life scores in patients consuming below and above the 800 mg carbidopa/levodopa threshold, though a mild worsening in dyskinesia duration was noted without worsening in dyskinesia pain and disability. In PD patients who crossed the 800 mg threshold between two consecutive clinic visits, a significant improvement in depressive symptoms and quality-of-life measures was demonstrated, and in these patients there was no worsening of motor fluctuations or dyskinesia.

Conclusions: The data suggest that PD patients have the potential for enhanced clinical benefits when eclipsing the 800 mg carbidopa/levodopa threshold. Many patients will likely need to eclipse the 800 mg threshold and pharmacies and insurance companies should be aware of the requirements that may extend beyond approval limits.

INTRODUCTION
Carbidopa/levodopa has been the most effective first-line pharmacological therapy in the treatment of Parkinson’s disease (PD).1,2 When approved by the Food and Drug Administration (FDA) in 1988, a maximum dosage threshold of eight 100 mg pills/day was written in as the limit. This limit was based on animal studies which revealed, ‘a significant proportion of infant rats of both sexes are expected to die at a dose of 800 mg/kg’.3 FDA authorisation was a historic success; however, the carbidopa/levodopa limit has resulted in important issues for patients and for clinicians. The limit
commonly shows up in many online medical record systems, pharmacies and websites. The limit has also been widely cited in coverage decisions by insurance providers seeking to limit the number of tablets dispensed to a single PD sufferer.

It is well known and appreciated that many patients, especially those with advanced PD, will require frequent doses in excess of 800 mg a day. The current limit sets up a potentially worrisome scenario for patients requiring more than 800 mg a day of dopamine replacement. Carbidopa/levodopa plays an important role in the management of PD by symptomatically addressing many of its disabling disease manifestations including tremor, rigidity, bradykinesia, postural instability, gait issues and also some non-motor features.2 Under-medication can contribute to destabilising the clinical features of the disease and could lead to an increased risk of falls and aspiration pneumonia.4 As PD progresses, many patients eclipse eight 100 mg pills a day, and will ultimately require greater amounts of levodopa to be taken at more frequent medication intervals (eg, every 2 hours).

There have been few studies that have specifically investigated the carbidopa/levodopa dose-response.3–5 No study has specifically addressed the 800 mg threshold question. In this investigation, we examined the clinical consequences of crossing the 800 mg threshold. We hypothesised that crossing the 800 mg threshold would lead to general improvement in clinical symptoms without adding significant safety issues.

**METHODS**

Data were obtained following informed consent and through the use of the Institutional Review Board-approved protocol for the University of Florida-INFORM (Interdisciplinary Florida Registry and Movement Disorders) database. All patients treated with carbidopa/levodopa (Sinemet, Stalevo, Parcopa) from July 2002 to December 2009 were included. Inclusion criteria required a diagnosis of idiopathic PD using UK Brain Bank criteria8 according to a movement disorders trained specialist. Patients with deep brain stimulation devices were excluded. It was required that the Unified Parkinson’s Disease Rating Scale (UPDRS), the Parkinson’s Disease Quality of Life Questionnaire (PDQ-39) and the Beck Depression Inventory (BDI) were administered to all patients at each clinical visit. The strict criteria were employed to limit variability in the comparisons.

The first analysis was between-group, examining those patients above and those patients below a daily levodopa dosage threshold of 800 mg. Each group was limited to Hoehn-Yahr stages 2, 2.5 and 3 and to a disease duration of 5–10 years. Figure 1 summarises the data used in this analysis, and the reasons for exclusion. The threshold was determined at each subject’s first visit to the University of Florida Center for Movement Disorders and Neurorestoration. The mean levodopa dosage, Hoehn-Yahr Parkinson stage and disease duration for the two groups (above and below 800 mg) were documented. In addition, the UPDRS Part III motor score in the ‘on’ dopaminergic medication state, the UPDRS Part IV motor fluctuations and dyskinesia subscores, the PDQ-39 quality-of-life score, and the BDI depression score were used in the analysis, and in the between-groups comparison. The Wilcoxon rank-sum test was used to detect significant differences between groups for the BDI, PDQ-39 and UPDRS motor scales. The χ² test was used to identify differences in agonist use, and Fisher’s exact test was utilised for the categorical dyskinesia questions. In each dyskinesia question, categories 2–4 were combined. In addition, the levodopa dosage, the levodopa equivalent dose9 and the use of dopamine agonists were documented. The disease characteristics for each group have been summarised in table 1.

A second analysis was performed using patients who crossed the threshold (moving above 800 mg) when tracked for two consecutive clinic visits. For this analysis, the following criteria were employed: (1) at the first clinic visit the dosage had to be below or equal to 800 mg and (2) at the second clinic visit the dosage had to be above 800 mg. The second visit was required to be within 1 year of the first visit in order to minimise the...
effects of disease progression. The UPDRS Part III, UPDRS Part IV, PDQ-39, BDI and dyskinesia subscores from each clinic visit were compared using the paired Wilcoxon signed-rank test. The Cochran Q test was used to identify differences in the dyskinesia questions, and the McNemar test was used for agonist analysis. Table 2 summarises the findings.

The α was set at \( p<0.01 \) because multiple comparisons were performed. IBM SPSS Statistics V.20 was used for all analysis.

### RESULTS

The between-group analysis revealed that 195 PD patients met inclusion criteria (151 were below the 800 mg threshold and 44 above). The disease characteristics have been summarised in Table 1. The mean levodopa doses were 470.5 mg for the below-threshold group and 1212.8 mg for the above-threshold group. The LED (which takes into account all dopaminergic drugs) was also calculated.9

Dyskinesia information was available for 185/195 patients (94.9%). The Wilcoxon rank-sum test revealed worsening in dyskinesia duration as measured by question 32 from the UPDRS Part IV scale (\( p<0.01 \)) for the above 800 mg threshold group. Though dyskinesia duration slightly worsened, dyskinesia pain and dyskinesia disability did not significantly differ between groups. The remaining scales (UPDRS Part III, PDQ-39 QOL, BDI) did not reveal significant between group differences.

A longitudinal analysis between two clinic visits was then performed. A sample of 28 patients drawn from the above group who crossed the 800 mg threshold from visits 1 to 2 was identified. The second appointment was an average of 229 days from the first, with a standard deviation of 95. The disease characteristics of the longitudinal cohort have been summarised in Table 2. Utilising the Wilcoxon signed rank test, improvements in QOL (\( p<0.01 \)) and depressive symptoms according to BDI (\( p<0.001 \)) were revealed in the group that exceeded 800 mg (Figure 2A,B). Changes in motor score and dyskinesia categories were not significantly different between groups.

### DISCUSSION

The data from this study revealed that eclipsing the 800 mg levodopa threshold was associated with mild worsening of dyskinesia symptoms without worsening disability, while maintaining benefit in motor, mood and quality-of-life scales. Further, a longitudinal analysis performed between two consecutive clinic visits revealed that depressive symptoms and quality of life improved.
when crossing the threshold. Early in the course of PD treatment, patients typically use two or three 100 mg pills a day to maintain what has been referred to as an ‘on’ medication state. This has also been referred to as the ‘honeymoon period’. Tremors, stiffness, slowness and other symptoms typically improve during the ‘on’ medication state. However, following 5 years of PD duration, the majority of patients experience a wearing-off effect between their dosages, and also on–off fluctuations. In addition, many patients experience hyperkinetic movements referred to as dyskinesia.9 Immediate-release levodopa is associated with a short half-life (approximately 90 min), and intraneuronal buffering most likely contributes to near-continuous stimulation between dosages.10 As PD progresses, however, this buffering capacity seems to diminish with the loss of nigrostriatal terminals, and plasma levels fluctuate more frequently.10 9 As the disease duration increases, levodopa doses typically increase, and must be administered at closer intervals in order to avoid motor fluctuations. Some PD patients will actually require doses to be administered as frequently as every 2 hours all day and possibly during the night. It is also important to note that similar doses of different standard oral carbidopa/levodopa formulations will likely manifest different clinical and pharmacological effects. Further, continuous intrajejunal infusion of levodopa has been observed to have a different benefit and side effect profile relative to traditional oral levodopa administered at similar doses. In one study, an intrajejunal levodopa infusion of 1996 ±675 mg/day (range, 1100–3204 mg/day) led to significant improvement with few side effects.11 This dosage was well above the 800 mg FDA limit, and this provides further evidence that the pill limit should be revisited.

The current study used two methodologies to examine key disease characteristics of patients below and above the 800 mg levodopa threshold set by the FDA in 1988. PD patients in our study tolerated a levodopa dosage increase to above the 800 mg threshold, though there was an expected modest increase in dyskinesia duration, but not disability with escalation of dosages in the between-group scenario. Interestingly, patients in the longitudinal analysis did not worsen in any of the dyskinesia categories, highlighting the notion that careful medication titration by experienced practitioners can limit adverse side effects of dopaminergic therapy. No study has followed up on the animal toxicity data that were quoted in the FDA approval letter for carbidopa/levodopa.3 There are however, several important published observations on carbidopa/levodopa. An animal study using hemiparkinsonian monkeys observed that optimal antiparkinsonian effects occurred at

### Table 2

|                      | Visit 1          | Visit 2          | p Value   |
|----------------------|------------------|------------------|-----------|
| Count                | 28               | –                | NA        |
| Age (years)          | 72.29 (10.02)    | –                | NS        |
| Disease Duration (years) | 6.93 (3.85)     | –                | NS        |
| Agonist present*    | 14, 50%          | 12, 42.9%        | NS        |
| Dose (mg)            | 585.29 (166.38)  | 1102.50 (237.15) | <0.0001   |
| LED (mg)             | 664.23 (239.54)  | 1162.11 (245.11) | <0.0001   |
| UPDRS Part III       | 31.86 (10.68)    | 28.75 (8.36)     | NS        |
| PDQ-39 QOL           | 32.79 (17.69)    | 27.69 (21.31)    | <0.01     |
| BDI                  | 12.82 (9.44)     | 10.04 (8.47)     | <0.01     |
| Dyskinesia duration, Q32 |                    |                  | 0.572     |
| 0%                   | 19 (51.4%)       | 18 (48.6%)       |           |
| 1–25%                | 3 (37.5%)        | 5 (62.5%)        |           |
| 26–100%              | 4 (44.4%)        | 5 (55.6%)        |           |
| Dyskinesia disability, Q33 |                    |                  | 0.572     |
| None                 | 22 (48.9%)       | 23 (51.1%)       |           |
| Mild                 | 2 (40.0%)        | 3 (60.0%)        |           |
| Moderate, severe     | 3 (60.0%)        | 2 (40.0%)        |           |
| Dyskinesia pain, Q34 |                    |                  | NA†       |
| None                 | 26 (50.0%)       | 26 (50.0%)       |           |
| Slight               | 2 (100.0%)       |                  |           |
| Moderate, severe     |                  |                  |           |
| Percent of day OFF Medication, Q39 |                |                  | 0.521     |
| 0%                   | 7 (53.8%)        | 6 (46.2%)        |           |
| 1–25%                | 13 (50.0%)       | 13 (50.0%)       |           |
| 26–100%              | 6 (40.0%)        | 9 (60.0%)        |           |

Standard deviation in parenthesis
NS, not statistically significant; NA, not applicable
*Number of records where agonist is present
†Dyskinesia Q34 has only one group at visit 1—the associated test could not be carried out.

Brodell DW, Stanford NT, Jacobson CE, et al. BMJ Open 2012;2:e001971. doi:10.1136/bmjopen-2012-001971
be employed to limit motor fluctuations, but as disease duration increases, typically the medication interval decreases, and the levodopa dosage will quickly escalate above the 800 mg threshold in the majority of sufferers.13

One limitation of our study was the exclusion of a large number of PD patients who were on levodopa replacement therapy. This exclusion was purposeful, as we sought to narrow the groups above and below 800 mg to be comparable on all major disease state measures. A further limitation was that the scales were drawn from a clinical research database, which through a single centre utilised multiple independent fellowship trained movement disorders specialists to perform the ratings. All specialists were specifically trained with the Movement Disorders Society UPDRS training tape; however, this process could have introduced variability. The patients were, however, seen by the same neurologist from visit to visit. In addition, the lack of blinding may have introduced bias. Additionally, the measurement of motor fluctuations and dyskinesias was limited by the use of categorical questions from the UPDRS Part IV, rather than by the gold standard 2-day on–off fluctuation diary.14 Also, it should be considered that higher dosages of levodopa are often frequently paired with lower dosages of dopamine agonists and this could have affected the findings. Finally, in future studies, other safety measures should be documented including hallucinations, nausea, daytime sleepiness, orthostatic hypotension and even death as documentation of a favourable safety record would also support eclipsing the 800 mg threshold. The establishment of a multicenter prospective database to comprehensively track PD medications, dosages and side effects could be useful to the field.

In conclusion, the data suggest that PD patients may achieve an enhanced benefit when eclipsing the 800 mg levodopa threshold that has been imposed by the FDA. The treatment of advanced PD will frequently require the clinician to administer more than 800 mg of levodopa per day, and therefore we conclude that it would be reasonable for the FDA to consider revision of its recommendation. This revision would enable online medical record systems, pharmacies and insurance carriers to act on the critical need that many PD patients have for more than eight carbidopa/levodopa tablets each day.

Acknowledgements We would like to acknowledge the support of the National Parkinson Foundation Center of Excellence and the UF INFORM database.

Contributors PS and MO were involved in study conception and design; CJ and DB were involved in acquisition of data; DB and MO carried out primary analysis, organisation and interpretation; DB and NS were involved in primary writing; MO, DB, CJ and PS performed critical revisions and MO supervised the study.

Funding This study was supported financially by the grant support provided by the National Parkinson Foundation Center of Excellence located at the University of Florida, Gainesville. MO serves as a consultant for the National Parkinson Foundation, and has received research grants from NIH, NPF, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation and the UF Foundation. MO has in the past >36 months received no support from industry. MO has received royalties for publications with Demos, Manson and

**Figure 2** (A) Improvement in quality of life when increasing above the 800 mg levodopa threshold. (B) Improvement in depressive symptoms when increasing above the 800 mg levodopa threshold.
Cambridge (movement disorders books). MO has participated in CME activities on movement disorders sponsored by the USF CME office, Prime, Delaware Media, Journal Watch, PeerView and by Vanderbilt University. The institution and not MO receives grants from Medtronic and ANS/St Jude, and the PI has no financial interest in these grants. MO has participated as a site PI and/or co-I for several NIH, foundation, and industry sponsored trials over the years, but has not received honoraria. Publication of this article was funded in part by the University of Florida Open-Access Publishing Fund.

**Competing interests** DB, NS, CJ and PS have nothing to disclose.

**Ethics approval** The University of Florida Institutional Review Board (IRB-01).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** Please contact CJ at jacobson@neurology.ufl.edu for access.

**REFERENCES**

1. Jain L, Benko R, Safranek S. Clinical inquiry. Which drugs work best for early Parkinson’s disease? J Fam Pract 2012;61:106–8.
2. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. J Neurol 2002;58:11–17.
3. Merck & Co., Inc. United States. Food and Drug Administration. Sinemet 1988.
4. Temlett JA, Thompson PD. Reasons for admission to hospital for Parkinson’s disease. J Intern Med 2006;36:524–6.
5. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA Trial. Earlier vs later L-DOPA. Arch Neurol 1999;56:529–35.
6. Kurlan R, Kim MH, Gash DM. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov Disord 1991;6:111–18.
7. Nyholm D, Karlsson E, Lundberg M, et al. Large differences in levodopa dose requirement in Parkinson’s disease: men use higher doses than women. Eur J Neurol 2010;17:260–6.
8. Hughes AJ, Daniel SE, Ben-Schlomo Y, et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:661–70.
9. Hobson DE, Lang AE, Martin WR, et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002;287:455–63.
10. Poewe W, Antonini A, Zijlmans JC, et al. Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. Clin Interv Aging 2010;5:229–38.
11. Reddy P, Martinez-Martin P, Rizos A, et al. Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin Neuropharmacol 2012;35:205–7.
12. Lu LH, Barnett AM, Cibula JE, et al. Dissociation of anosognosia and phantom movement during the Wada test. J Neurol Neurosurg Psychiatry 2000;69:820–3.
13. Khlebtovsky A, Rigbi A, Melamed E, et al. Patient and caregiver perceptions of the social impact of advanced Parkinson’s disease and dyskinesias. J Neural Transm 2012;119:1367–71.
14. Papapetropoulos SS. Patient diaries as a clinical endpoint in Parkinson’s disease clinical trials. CNS Neurosci Ther 2012;18:380–7.